Emily R.M. Sydnor Spivak
No Rating Available
(Learn About Our Rating System)

Emily R.M. Sydnor Spivak, MD, MHS

Languages spoken: English

Clinical Locations

Primary Location

University of Utah Hospital

Infectious Diseases, Area E
50 N Medical Dr
Salt Lake City , UT 84132
801-585-2031
Get Directions

  • Dr. Spivak is a Professor of Medicine in the Division of Infectious Diseases. She established and serves as Co-Director of the Antimicrobial Stewardship Programs at University of Utah Health and the Salt Lake City Veterans Affairs Healthcare System. She completed her residency and fellowship training at the Johns Hopkins University School of Medicine and earned a Masters in Health Sciences in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health.

    Dr. Spivak's research interests focus on understanding patterns and drivers of antimicrobial use, methods to assess appropriateness, and development and evaluation of methods to improve antimicrobial use. She has led clinical research focused on evaluating patient outcomes related to various antibiotic use strategies. She is also involved with national Veterans Affairs efforts to evaluate antimicrobial use, develop tools to improve use and dissemination and evaluation of these resources.

    She is a member of the Society of Healthcare Epidemiology (SHEA) where she serves on the Public Policy and Government Affairs Committee and the Antibiotic Stewardship Committee. She is a Fellow of the Infectious Diseases Society of America (IDSA), and serves as Vice Chair of the IDSA Antimicrobial Resistance Committee. She also serves as a member of the Board of Scientific Counselors to the Office of Infectious Diseases at the Centers for Disease Control and Prevention, and is Co-Chair of the Vizient Antimicrobial Stewardship Committee.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Infectious Disease)

  • Dr. Spivak is a Professor of Medicine in the Division of Infectious Diseases. She established and serves as Co-Director of the Antimicrobial Stewardship Programs at University of Utah Health and the Salt Lake City Veterans Affairs Healthcare System. She completed her residency and fellowship training at the Johns Hopkins University School of Medicine and earned a Masters in Health Sciences in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health.

    Dr. Spivak's research interests focus on understanding patterns and drivers of antimicrobial use, methods to assess appropriateness, and development and evaluation of methods to improve antimicrobial use. She has led clinical research focused on evaluating patient outcomes related to various antibiotic use strategies. She is also involved with national Veterans Affairs efforts to evaluate antimicrobial use, develop tools to improve use and dissemination and evaluation of these resources.

    She is a member of the Society of Healthcare Epidemiology (SHEA) where she serves on the Public Policy and Government Affairs Committee and the Antibiotic Stewardship Committee. She is a Fellow of the Infectious Diseases Society of America (IDSA), and serves as Vice Chair of the IDSA Antimicrobial Resistance Committee. She also serves as a member of the Board of Scientific Counselors to the Office of Infectious Diseases at the Centers for Disease Control and Prevention, and is Co-Chair of the Vizient Antimicrobial Stewardship Committee.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor (Clinical)
    Academic Divisions Infectious Diseases
    Board Certification
    American Board of Internal Medicine (Sub: Infectious Disease)

    Education history

    Undergraduate Biology - The College of William and Mary B.S.
    Professional Medical Medicine - University of Virginia School of Medicine M.D.
    Internship Internal Medicine - Beth Israel Deaconess Medical Center Intern
    Residency Internal Medicine - Johns Hopkins University School of Medicine Resident
    Fellowship Infectious Diseases - Johns Hopkins University School of Medicine Fellow
    Chief Resident Internal Medicine - Osler Medical Service, Johns Hopkins University School of Medicine Chief Resident
    Graduate Training Clinical Investigation - Johns Hopkins Bloomberg School of Public Health M.H.S.

    Selected Publications

    Journal Article

    1. Goates C, Tsuha S, Working S, Carey J, Spivak E (2017). Seronegative West Nile Virus Infection in a Patient Treated with Rituximab for Rheumatoid Arthritis. The American journal of medicine, 130(6), e257-e258. (Read full publication)
    2. Emily R.M. Sydnor MD, MHS, Amy Greer PhD, Alicia P. Budd MPH, Miriana Pehar RN, Supriya Munshaw PhD, Dionissios Neofytos MD, Trish M. Perl MD, MSc, Alexandra Valsamakis MD, Ph (2012). An outbreak of human parainfluenza virus 3 infection in an outpatient hematopoietic stem cell transplantation clinic. American journal of infection control, 40(7), 601-5.
    3. Benefield RJ, Slechta ES, Gast CM, Spivak ES, Hanson KE, Alexander D (2018). Comparison of the drug-drug interaction potential of daptomycin in combination with rifampin in healthy adult volunteers. Antimicrobial agents and chemotherapy, Epub ahead.
    4. Timbrook TT, McKay L, Sutton JD, Spivak E (2020). Disproportionality Analysis of Safety With Nafcillin and Oxacillin With the FDA Adverse Event Reporting System (FAERS). Antimicrobial agents and chemotherapy, 64(3), e01818-19.
    5. Oliver MB, Fong K, Certain L, Spivak ES, Timbrook T (2021). Validation of a Community-Acquired Pneumonia Score To Improve Empiric Antibiotic Selection at an Academic Medical Center. Antimicrobial agents and chemotherapy, 65(2), (Read full publication)
    6. Timbrook TT, McKay L, Sutton JD, Spivak E (2020). Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS). Antimicrobial agents and chemotherapy, 64(3), (Read full publication)
    7. Benefield RJ, Slechta ES, Gast CM, Spivak ES, Hanson KE, Alexander D (2018). Comparison of the Drug-Drug Interaction Potential of Daptomycin in Combination with Rifampin in Healthy Adult Volunteers. Antimicrobial agents and chemotherapy, 62(12), (Read full publication)
    8. Tamma PD, Turnbull AE, Milstone AM, Lehmann CU, Sydnor ER, Cosgrove S (2011). Ventilator-associated tracheitis in children: does antibiotic duration matter?. Clinical infectious diseases, 52(11), 1324-31. (Read full publication)
    9. Spivak ES, Burk M, Zhang R, Jones MM, Neuhauser MM, Goetz MB, Cunningham F (2017). Management of Bacteriuria in Veterans Affairs Hospitals. Clinical infectious diseases, 65(6), 910-917.
    10. Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers H (2018). Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting. Clinical infectious diseases, 67(8), 1168-1174.
    11. Fowler VG, Jezek A, Spivak ES, Talkington (2021). Urgent, Comprehensive Federal Action Needed To Stem Mortality and Medicare Costs Associated With Antimicrobial Resistance. Clinical infectious diseases, (Read full publication)
    12. Vaughn VM, Hersh AL, Spivak E (2021). Antibiotic Overuse and Stewardship at Hospital Discharge: The Reducing Overuse of Antibiotics at Discharge (ROAD) Home Framework. Clinical infectious diseases, (Read full publication)
    13. Madaras-Kelly K, Hostler C, Townsend M, Potter EM, Spivak ES, Hall SK, Goetz MB, Nevers M, Ying J, Haaland B, Rovelsky SA, Pontefract B, Fleming-Dutra K, Hicks LA, Samore M (2021). Impact of Implementation of the Core Elements of Outpatient Antibiotic Stewardship Within Veterans Health Administration Emergency Departments and Primary Care Clinics on Antibiotic Prescribing and Patient Outcomes. Clinical infectious diseases, 73(5), e1126-e1134. (Read full publication)
    14. Rhoads JLW, Willson TM, Sutton JD, Spivak ES, Samore MH, Stevens V (2021). Epidemiology, Disposition, and Treatment of Ambulatory Veterans With Skin and Soft Tissue Infections. Clinical infectious diseases, 72(4), 675-681. (Read full publication)
    15. Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers H (2018). Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting. Clinical infectious diseases, 67(8), 1168-1174. (Read full publication)
    16. Spivak ES, Neuhauser MM, Zhang R, Goetz MB, Cunningham F (2018). Reply to Johnson. Clinical infectious diseases, 66(11), 1817. (Read full publication)
    17. Spivak ES, Burk M, Zhang R, Jones MM, Neuhauser MM, Goetz MB, Cunningham FE, Management of Urinary Tract Infections Medication Use Evaluation Group ., Management of Urinary Tract Infections Medication Use Evaluation Group (2017). Management of Bacteriuria in Veterans Affairs Hospitals. Clinical infectious diseases, 65(6), 910-917. (Read full publication)
    18. Spivak ES, Cosgrove SE, Srinivasan (2016). Measuring Appropriate Antimicrobial Use: Attempts at Opening the Black Box. Clinical infectious diseases, 63(12), 1639-1644. (Read full publication)
    19. Dufresne SF, Marr KA, Sydnor E, Staab JF, Karp JE, Lu K, Zhang SX, Lavallée C, Perl TM, Neofytos (2014). Epidemiology of Candida kefyr in patients with hematologic malignancies. Journal of clinical microbiology, 52(6), 1830-7.
    20. Spivak ES, Hanson K (2018). Candida auris: an Emerging Fungal Pathogen. Journal of clinical microbiology, 56(2), (Read full publication)
    21. Sydnor ER, Bova G, Gimburg A, Cosgrove SE, Perl TM, Maragakis L (2012). Electronic Eye Faucets: Legionella spp. Contamination in Healthcare Settings. Infection control and hospital epidemiology, 33(3), 235-40.
    22. Sydnor ER, Lenhart A, Trollinger B, Avdic E, Maragakis LL, Carroll KC, Cosgrove S (2011). Antimicrobial Prescribing Practices in Response to Different Clostridium difficile Diagnostic Methodologies. Infection control and hospital epidemiology, 32(11), 1133-6.
    23. Spivak ES, Kendall B, Orlando P, Perez C, De Amorim M, Samore M, Pavia AT, Hersh A (2015). Evaluation of Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Hospital. Infection control and hospital epidemiology, 26, 1-3.
    24. Spivak ES, Kendall B, Orlando P, Perez C, De Amorim M, Samore M, Pavia AT, Hersh A (2015). Evaluation of Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Hospital. Infection control and hospital epidemiology, 36(9), 1103-5.
    25. Spivak ES, Kendall B, Orlando P, Perez C, De Amorim M, Samore M, Pavia AT, Hersh A (2015). Evaluation of Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Hospital. Infection control and hospital epidemiology, 36(9), 1103-5. (Read full publication)
    26. Lindgren KE, Pelt CE, Anderson MB, Peters CL, Spivak ES, Gililland J (2018). Corrigendum to 'A Chlorhexidine Solution Reduces Aerobic Organism Growth in Operative Splash Basins in a Randomized Controlled Trial' [Journal of Arthroplasty (2018) 211-215]. The Journal of arthroplasty, 33(4), 1305. (Read full publication)
    27. Lindgren KE, Pelt CE, Anderson MB, Peters CL, Spivak ES, Gililland J (2018). A Chlorhexidine Solution Reduces Aerobic Organism Growth in Operative Splash Basins in a Randomized Controlled Trial. The Journal of arthroplasty, 33(1), 211-215. (Read full publication)
    28. Timbrook TT, Spivak ES, Hanson K (2018). Current and Future Opportunities for Rapid Diagnostics in Antimicrobial Stewardship. The Medical clinics of North America, 102(5), 899-911. (Read full publication)
    29. Fox ER, Shah M, Vinik R, Brown S, Buckel W, Webb B, Zarndt J, Evans M, Mesdaghi P, Imlay HN, Spivak E (2021). Developing statewide remdesivir use criteria. American journal of health-system pharmacy, 78(8), 732-735. (Read full publication)
    30. Rhodes NJ, Dairem A, Moore WJ, Shah A, Postelnick MJ, Badowski ME, Michienzi SM, Borkowski JL, Polisetty RS, Fong K, Spivak ES, Beardsley JR, Hale CM, Pallotta AM, Srinivas P, Schulz L (2021). Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. American journal of health-system pharmacy, 78(7), 568-577. (Read full publication)
    31. Manabe YC, Campbell JD, Sydnor E, Moore R (2007). Immune reconstitution inflammatory syndrome: risk factors and treatment implications. Journal of acquired immune deficiency syndromes (1999), 46(4), 456-62. (Read full publication)
    32. Lynch L, Spivak E (2015). The pregnant healthcare worker: fact and fiction. Current opinion in infectious diseases, 28(4), 362-8. (Read full publication)
    33. Yarbrough PM, Kukhareva PV, Spivak ES, Hopkins C, Kawamoto (2015). Evidence-based care pathway for cellulitis improves process, clinical, and cost outcomes. Journal of hospital medicine, 10(12), 780-6.
    34. Yarbrough PM, Kukhareva PV, Spivak ES, Hopkins C, Kawamoto (2015). Evidence-based care pathway for cellulitis improves process, clinical, and cost outcomes. Journal of hospital medicine, 10(12), 780-6. (Read full publication)
    35. Guan J, Spivak ES, Wilkerson C, Park M (2017). Subdural Empyema in the Setting of Multimodal Intracranial Monitoring. World neurosurgery, 97, 749.e1-749.e6. (Read full publication)
    36. Buss BA, Baures TJ, Yoo M, Hanson KE, Alexander DP, Benefield RJ, Spivak E (2018). Impact of a Multiplex PCR Assay for Bloodstream Infections With and Without Antimicrobial Stewardship Intervention at a Cancer Hospital. Open forum infectious diseases, 5(10), ofy258.
    37. Erickson RM, Tritle BJ, Spivak ES, Timbrook T (2019). Impact of an Antimicrobial Stewardship Bundle for Uncomplicated Gram-Negative Bacteremia. . Open forum infectious diseases, 6(12),
    38. Sutton JD, Carico R, Burk M, Jones MM, Wei X, Neuhauser MM, Goetz MB, Echevarria KL, Spivak ES, Cunningham FE; Skin and Soft Tissue Infection Medication Use Evaluation Grou (2020). Inpatient Management of Uncomplicated Skin and Soft Tissue Infections in 34 Veterans Affairs Medical Centers: A Medication Use Evaluation. . Open forum infectious diseases, 7(1), ofz554.
    39. Ihm C, Sutton JD, Timbrook TT, Spivak E (2019). Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure. Open forum infectious diseases, 6(6), ofz217.
    40. Webb BJ, Buckel W, Vento T, Butler AM, Grisel N, Brown SM, Peltan ID, Spivak ES, Shah M, Sakata T, Wallin A, Stenehjem E, Poulsen G, Bledsoe (2021). Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. Open forum infectious diseases, 8(7), ofab331. (Read full publication)
    41. Gibson EG, Pender M, Angerbauer M, Cook C, Jones B, Spivak AM, Spivak ES, Swaminathan (2021). Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis. Open forum infectious diseases, 8(7), ofab176. (Read full publication)
    42. Eudy JL, Pallotta AM, Neuner EA, Brummel GL, Postelnick MJ, Schulz LT, Spivak ES, Wrenn R (2020). Antimicrobial Stewardship Practice in the Ambulatory Setting From a National Cohort. Open forum infectious diseases, 7(11), ofaa513. (Read full publication)
    43. Ciarkowski CE, Timbrook TT, Kukhareva PV, Edholm KM, Hatton ND, Hopkins CL, Thomas F, Sanford MN, Igumnova E, Benefield RJ, Kawamoto K, Spivak E (2020). A Pathway for Community-Acquired Pneumonia With Rapid Conversion to Oral Therapy Improves Health Care Value. Open forum infectious diseases, 7(11), ofaa497. (Read full publication)
    44. Sutton JD, Carico R, Burk M, Jones MM, Wei X, Neuhauser MM, Goetz MB, Echevarria KL, Spivak ES, Cunningham FE, Skin and Soft Tissue Infection Medication Use Evaluation Group (2020). Inpatient Management of Uncomplicated Skin and Soft Tissue Infections in 34 Veterans Affairs Medical Centers: A Medication Use Evaluation. Open forum infectious diseases, 7(1), ofz554. (Read full publication)
    45. Erickson RM, Tritle BJ, Spivak ES, Timbrook T (2019). Impact of an Antimicrobial Stewardship Bundle for Uncomplicated Gram-Negative Bacteremia. Open forum infectious diseases, 6(12), ofz490. (Read full publication)
    46. Ihm C, Sutton JD, Timbrook TT, Spivak E (2019). Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure. Open forum infectious diseases, 6(6), ofz217. (Read full publication)
    47. Buss BA, Baures TJ, Yoo M, Hanson KE, Alexander DP, Benefield RJ, Spivak E (2018). Impact of a Multiplex PCR Assay for Bloodstream Infections With and Without Antimicrobial Stewardship Intervention at a Cancer Hospital. Open forum infectious diseases, 5(10), ofy258. (Read full publication)
    48. Sutton JD, Sayood S, Spivak E (2018). Top Questions in Uncomplicated, Non-Staphylococcus aureus Bacteremia. Open forum infectious diseases, 5(5), ofy087. (Read full publication)
    49. Gruninger RJ, Johnson RA, Das SK, Nelson EJ, Spivak ES, Contreras JR, Faruque AS, Leung D (2017). Socioeconomic Determinants of Ciprofloxacin-resistant Shigella Infections in Bangladeshi Children. Pathogens & immunity, 2(1), 89-101.
    50. Gruninger RJ, Johnson RA, Das SK, Nelson EJ, Spivak ES, Contreras JR, Faruque ASG, Leung D (2017). Socioeconomic Determinants of Cipro-floxacin-Resistant Shigella Infections in Bangladeshi Children. Pathogens & immunity, 2(1), 89-101. (Read full publication)
    51. Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, Spivak AM, Steinbach M, Blaylock RC, Avila SV, Hankey KG, Martins TB, Slev PR, Mannuel HD, Sajadi M, Rapoport AP, Atanackovic (2020). Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood advances, 4(19), 4864-4868. (Read full publication)
    52. Sutton JD, Stevens VW, Chang NN, Khader K, Timbrook TT, Spivak E (2020). Oral ß-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source. JAMA network open, 3(10), e2020166. (Read full publication)
    53. Spivak E (2019). Antibiotic Use in Dentistry-What We Know and Do Not Know. JAMA network open, 2(5), e193881. (Read full publication)
    54. Shah KS, Reyes-Miranda AE, Bradley SM, Breathett K, Das SR, Gluckman TJ, Gupta D, Leung DT, Mutharasan RK, Peterson PN, Spivak ES, Shah R (2022). Clinical Trial Participation and COVID-19: a Descriptive Analysis from the American Heart Association's Get With The Guidelines Registry. Journal of racial and ethnic health disparities, (Read full publication)
    55. Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley D (2022). Early Outpatient Treatment for Covid-19 with Convalescent Plasma. The New England journal of medicine, (Read full publication)
    56. Claeys KC, Trautner BW, Leekha S, Coffey KC, Crnich CJ, Diekema D, Fakih MG, Goetz MB, Gupta K, Jones MM, Leykum L, Liang SY, Pineles L, Pleiss A, Spivak ES, Suda KJ, Taylor J, Rhee C, Morgan D (2021). Optimal Urine Culture Diagnostic Stewardship Practice- Results from an Expert Modified-Delphi Procedure. Clinical infectious diseases, (Read full publication)
    57. Webb BJ, Levin NM, Grisel N, Brown SM, Peltan ID, Spivak ES, Shah M, Stenehjem E, Bledsoe (2022). Simple scoring tool to estimate risk of hospitalization and mortality in ambulatory and emergency department patients with COVID-19. PloS one, 17(3), e0261508. (Read full publication)
    58. Vaughn VM, Giesler DL, Mashrah D, Brancaccio A, Sandison K, Spivak ES, Szymczak JE, Wu C, Horowitz JK, Bashaw L, Hersh A (2022). Pharmacist gender and physician acceptance of antibiotic stewardship recommendations: An analysis of the reducing overuse of antibiotics at discharge home intervention. Infection control and hospital epidemiology, 44(4), 1-8. (Read full publication)
    59. Rock C, Abosi O, Bleasdale S, Colligan E, Diekema DJ, Dullabh P, Gurses AP, Heaney-Huls K, Jacob JT, Kandiah S, Lama S, Leekha S, Mayer J, Mena Lora AJ, Morgan DJ, Osei P, Pau S, Salinas JL, Spivak E, Wenzler E, Cosgrove S (2022). Clinical Decision Support Systems to Reduce Unnecessary Clostridioides difficile Testing Across Multiple Hospitals. Clinical infectious diseases, 75(7), 1187-1193. (Read full publication)
    60. Baksh S, Heath SL, Fukuta Y, Shade D, Meisenberg B, Bloch EM, Tobian AAR, Spivak ES, Patel B, Gerber J, Raval JS, Forthal D, Paxton J, Mosnaim G, Anjan S, Blair J, Cachay E, Currier J, Das P, Huaman M, Sutcliffe C, Yarava A, Casadevall A, Sullivan D, Hanley D, Gebo KA, CSSC-004 Consortiu (2023). Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a randomized trial. The Journal of infectious diseases, (Read full publication)
    61. Wimmer MR, Schulz LT, Hamel AG, Schwei RJ, Fong K, Burgess DR, Brett M, Hale CM, Holubar M, Jain R, Larry R, Spivak ES, Newland H, Njoku J, Postelnick M, Walraven C, Pulia M (2022). The impact of coronavirus disease 2019 (COVID-19) on the antimicrobial stewardship pharmacist workforce: A multicenter survey. Antimicrobial stewardship & healthcare epidemiology, 2(1), e56. (Read full publication)
    62. Shulder S, Tamma PD, Fiawoo S, Dzintars K, Escobar D, Livorsi DJ, Malani AN, Palacio D, Spivak ES, Zimmerman M, Bork J (2023). Infectious Diseases Consultation Associated With Reduced Mortality in Gram-Negative Bacteremia. Clinical infectious diseases, 77(9), 1234-1237. (Read full publication)
    63. Huaman MA, Raval JS, Paxton JH, Mosnaim GS, Patel B, Anjan S, Meisenberg BR, Levine AC, Marshall CE, Yarava A, Shenoy AG, Heath SL, Currier JS, Fukuta Y, Blair JE, Spivak ES, Petrini JR, Broderick PB, Rausch W, Cordisco M, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Kassaye SG, Ram M, Wang Y, Das P, Lane K, McBee NA, Gawad AL, Karlen N, Ford DE, Laeyendecker O, Pekosz A, Klein SL, Ehrhardt S, Lau B, Baksh SN, Shade DM, Casadevall A, Hanley DF, Ou J, Gniadek TJ, Ziman A, Shoham S, Gebo KA, Bloch EM, Tobian AAR, Sullivan DJ, Gerber J (2023). Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials. Transfusion, 63(9), 1639-1648. (Read full publication)
    64. Ince D, Fiawoo S, Choudhury R, Cosgrove SE, Dobrzynski D, Gold H, Lee JH, Percival KM, Shulder S, Sony D, Spivak ES, Tamma PD, Nori (2023). Epidemiology of Gram-Negative Bloodstream Infections in the United States: Results From a Cohort of 24 Hospitals. Open forum infectious diseases, 10(7), ofad265. (Read full publication)
    65. Heil EL, Bork JT, Abbo LM, Barlam TF, Cosgrove SE, Davis A, Ha DR, Jenkins TC, Kaye KS, Lewis JS 2nd, Ortwine JK, Pogue JM, Spivak ES, Stevens MP, Vaezi L, Tamma P (2021). Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process. Open forum infectious diseases, 8(10), ofab434. (Read full publication)
    66. Timbrook TT, Prinzi AM, Spivak E (2023). Diagnostic and antimicrobial stewardship workforce challenges: A crisis in combating antimicrobial resistance. Antimicrobial stewardship & healthcare epidemiology, 3(1), e60. (Read full publication)
    67. Imlay H, Ciarkowski CE, Bryson-Cahn C, Chan JD, Hartlage WP, Hersh AL, Lynch JB, Martinez-Paz N, Spivak ES, Hardin H, White AT, Wu C, Kassamali Escobar Z, Vaughn V (2024). Validation and generalizability of an asymptomatic bacteriuria metric in critical access hospitals. Infection control and hospital epidemiology, 46(2), 1-6. (Read full publication)
    68. Ciarkowski CE, Imlay HN, Bryson-Cahn C, Chan JD, Hartlage W, Hersh AL, Lynch JB, Martinez-Paz N, Spivak ES, Hardin H, White AT, Wu C, Vaughn VM, Kassamali Escobar (2024). Antimicrobial stewardship to reduce overtreatment of asymptomatic bacteriuria in critical access hospitals: measuring a quality improvement intervention. Infection control and hospital epidemiology, 46(2), 1-7. (Read full publication)
    69. Kwon JH, Advani SD, Branch-Elliman W, Braun BI, Cheng VC, Chiotos K, Douglas P, Gohil SK, Keller SC, Klein EY, Krein SL, Lofgren ET, Merrill K, Moehring RW, Monsees E, Perri L, Scaggs Huang F, Shelly MA, Skelton F, Spivak ES, Sreeramoju PV, Suda KJ, Ting JY, Weston GD, Yassin MH, Ziegler MJ, Mody (2024). A call to action: the SHEA research agenda to combat healthcare-associated infections. Infection control and hospital epidemiology, 45(9), 1-18. (Read full publication)
    70. Imlay H, Greenlee SB, Tritle BJ, Fino NF, Spivak E (2024). In-person prospective audit and feedback on an oncology ward: development of an immunocompromised antimicrobial stewardship program. Antimicrobial stewardship & healthcare epidemiology, 4(1), e173. (Read full publication)
    71. Spivak ES, Tobin J, Hersh AL, Lee A (2024). Greenhouse gas emissions due to unnecessary antibiotic prescriptions. Antimicrobial stewardship & healthcare epidemiology, 4(1), e114. (Read full publication)
    72. Vaughn VM, Krein SL, Hersh AL, Buckel WR, White AT, Horowitz JK, Patel PK, Gandhi TN, Petty LA, Spivak ES, Bernstein SJ, Malani AN, Johnson LB, Neetz RA, Flanders SA, Galyean P, Kimball E, Bloomquist K, Zickmund T, Zickmund SL, Szymczak J (2024). Excellence in Antibiotic Stewardship: A Mixed-Methods Study Comparing High-, Medium-, and Low-Performing Hospitals. Clinical infectious diseases, 78(6), 1412-1424. (Read full publication)
    73. Wimmer MR, Griffin M, Peterson-Weber A, Schulz LT, Hamel AG, Schwei RJ, Fong K, Burgess DR, Brett M, Hale CM, Holubar M, Jain R, Larry R, Spivak ES, Newland H, Njoku J, Postelnick M, Walraven C, Pulia M (2024). Diagnostic testing and antibiotic utilization among inpatients evaluated for coronavirus disease 2019 (COVID-19) pneumonia. Infection control and hospital epidemiology, 45(5), 667-669. (Read full publication)
    74. Hersh AL, Stenehjem EA, Fino N, Spivak E (2024). Impact of COVID-19 on urgent care diagnoses and the new AXR metric. Antimicrobial stewardship & healthcare epidemiology, 4(1), e49. (Read full publication)
    75. Park HS, Yin A, Barranta C, Lee JS, Caputo CA, Sachithanandham J, Li M, Yoon S, Sitaras I, Jedlicka A, Eby Y, Ram M, Fernandez RE, Baker OR, Shenoy AG, Mosnaim GS, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Lau B, Ehrhardt S, Baksh SN, Shapiro JR, Ou J, Na YB, Knoll MD, Ornelas-Gatdula E, Arroyo-Curras N, Gniadek TJ, Caturegli P, Wu J, Ndahiro N, Betenbaugh MJ, Ziman A, Hanley DF, Casadevall A, Shoham S, Bloch EM, Gebo KA, Tobian AA, Laeyendecker O, Pekosz A, Klein SL, Sullivan D (2024). Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. JCI insight, 9(8), (Read full publication)
    76. Earl A, Greenlee S, Fong K, Imlay H, Spivak E (2023). Positivity of repeat nasal MRSA PCR screening: a single-center experience. Antimicrobial stewardship & healthcare epidemiology, 3(1), e226. (Read full publication)
    77. Gray J, Zhang C, Earl A, Spivak E (2025). Short versus long treatment duration for streptococcal bloodstream infection. Antimicrobial stewardship & healthcare epidemiology, 5(1), e47. (Read full publication)
    78. Payne J, Sutton JD, Blackburn BE, Bansod S, Imlay H, Spivak ES, Pupaibool J, Gililland JM, Certain L (2025). Effect of oral antibiotics after two-stage revision for periprosthetic joint infection on subsequent antibiotic resistance within a national cohort of United States veterans. Journal of bone and joint infection, 10(1), 7-14. (Read full publication)
    79. Fabre V, Hsu YJ, Carroll KC, Salinas AB, Gadala A, Bower C, Boyd S, Degnan KO, Dhaubhadel P, Diekema DJ, Drees M, Feeser B, Fisher MA, Flynn C, Ford B, Gettler EB, Glaser LJ, Howard-Anderson J, Johnson JK, Kim JJ, Martinez M, Mathers AJ, Mermel LA, Moehring RW, Nelson GE, O'Horo JC, Pepe DE, Robinson ED, Rodríguez-Nava G, Ryder JH, Salinas JL, Schrank GM, Shah A, Shelly M, Spivak ES, Stewart KO, Talbot TR, Van Schooneveld TC, Wasylyshyn A, Cosgrove SE, Centers for Disease Control and Prevention (CDC) Prevention Epicenters Progra (2025). Blood Culture Use in Medical and Surgical Intensive Care Units and Wards. JAMA network open, 8(1), e2454738. (Read full publication)
    80. Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley D (2021). Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. (Read full publication)
    81. Park HS, Yin A, Barranta C, Lee JS, Caputo CA, Sachithanandham J, Li M, Yoon S, Sitaras I, Jedlicka A, Eby Y, Ram M, Fernandez RE, Baker OR, Shenoy AG, Mosnaim GS, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Lau B, Ehrhardt S, Baksh SN, Shapiro JR, Ou J, Na YB, Knoll MD, Ornelas-Gatdula E, Arroyo-Curras N, Gniadek TJ, Caturegli P, Wu J, Ndahiro N, Betenbaugh MJ, Ziman A, Hanley DF, Casadevall A, Shoham S, Bloch EM, Gebo KA, Tobian AAR, Laeyendecker O, Pekosz A, Klein SL, Sullivan D (2023). Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. (Read full publication)
    82. Doernberg SB, Heil EL, Fiawoo S, Lee JH, Cosgrove SE, Dobrzynski DM, Li Y, Shields RK, Spivak ES, Stohs EJ, Tamma PD, McCreary E (2025). Epidemiology, Treatment, and Outcomes of Gram-Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients. Clinical transplantation, 39(4), e70160. (Read full publication)
    83. Moehring RW, Yarrington ME, Ashley ED, Addison RM, Buckel WR, Cosgrove SE, Doughman D, Klein E, Santos CAQ, Spivak ES, Trick W, Smith M, Weber DJ, Zhao C, Anderson DJ, Goldstein B (2025). Using Encounter-Level Data for Risk-Adjustment of Antimicrobial Use Comparisons: Feasibility and Variable Selection. Clinical infectious diseases, (Read full publication)
    84. Hojat LS, Veltri C, Newman NJ, Ferreira RE, Moore VL, Higbee-Todd KJ, Lee AP, Woods AG, Singer ME, Spivak E (2025). Development of a Novel Carbon Emissions Estimation Tool for Disposable Waste Associated With Antimicrobial Packaging, Preparation, and Administration in the Hospital Setting. Open forum infectious diseases, 12(10), ofaf308. (Read full publication)
    85. Goel D, Grimshaw M, Fino N, Spivak ES, Hersh A (2025). The relationship between antibiotic utilization for respiratory conditions (AXR) and antibiotic prescribing for pharyngitis. Antimicrobial stewardship & healthcare epidemiology, 5(1), e212. (Read full publication)
    86. Chakravorty AJ, Newman NJ, Veltri C, Spivak ES, Hecker MT, Hojat L (2025). Estimated greenhouse gas emissions associated with unnecessary intravenous antimicrobials administered in the hospital setting. Antimicrobial stewardship & healthcare epidemiology, 5(1), e263. (Read full publication)
    87. Fabre V, Hsu Y-J, Carroll KC, Milstone AM, Salinas AB, Abbo LM, Bower C, Berry J, Boyd S, Degnan KO, Dhaubhadel P, Diekema DJ, Dress M, Feeser B, Fisher M, Flynn C, Ford BA, Gettler EB, Glasser LJ, Howard-Anderson J, Johnson JK, Karaba SM, Kim JJ, Kubischta A, Landrum BM, Martinez M, Mathers AJ, Mermel L, Moehring RW, O'Horo JC, Pepe DE, Qasba SS, Rittmann B, Robinson ED, Rodríguez-Nava G, Rosa R, Ryder JH, Salinas JL, Shah A, Schrank GM, Shelly M, Spivak ES, Stewart KO, Talbot TR, Van Schooneveld TC, Wasylyshyn A, Gadala A, Virk Z, Cosgrove S (2025). Multicenter evaluation of blood culture contamination and blood cultures practices in US acute care hospitals: time for standardization. Journal of clinical microbiology, 63(8), e0053025. (Read full publication)

    Review

    1. Spivak ES, Cosgrove SE, Srinivasan (2016). Measuring Appropriate Antimicrobial Use: Attempts at Opening the Black Box. Clinical infectious diseases, 63(12), 1639-1644.
    2. Spivak AM, Sydnor ER, Blankson JN, Gallant J (2010). Seronegative HIV-1 infection: a review of the literature. AIDS (London, England), 24(10), 1407-14. (Read full publication)
    3. Sydnor ER, Perl T (2011). Hospital epidemiology and infection control in acute-care settings. Clinical microbiology reviews, 24(1), 141-73. (Read full publication)
    4. Spivak ES, Hanson K (2018). Candida auris: an Emerging Fungal Pathogen. Journal of clinical microbiology, 56(2), e01588-17.
    5. Timbrook TT, Spivak ES, Hanson K (2018). Current and Future Opportunities for Rapid Diagnostics in Antimicrobial Stewardship. The Medical clinics of North America, 102(5), 899-911.
    6. Sydnor E, Perl T (2014). Healthcare providers as sources of vaccine-preventable diseases. Vaccine, 32(38), 4814-4822.
    7. Lynch L, Spivak E (2015). The pregnant healthcare worker: fact and fiction. Current opinion in infectious diseases, 28(4), 362-8.
    8. Sutton JD, Sayood S, Spivak E (2018). Top Questions in Uncomplicated, Non-Staphylococcus aureus Bacteremia. Open forum infectious diseases, 5(5), ofy087.
    9. Hartlage W, Imlay H, Spivak E (2024). The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia. Antimicrobial stewardship & healthcare epidemiology, 4(1), e214. (Read full publication)

    Commentary

    1. Sutton JD, Spivak E (2023). Oral step-down with β-lactams for uncomplicated Enterobacterales bacteraemia. Clinical microbiology and infection, 29(4), 408-410. (Read full publication)

    Case Report

    1. Goates C, Tsuha S, Working S, Carey J, Spivak E (2017). Seronegative West Nile Virus Infection in a Patient Treated with Rituximab for Rheumatoid Arthritis. The American journal of medicine, 130(6), e257-e258.

    Editorial

    1. Spivak E (2019). Antibiotic Use in Dentistry-What We Know and Do Not Know. 2(5), e193881.
    2. Greenlee SB, Spivak E (2023). Antimicrobial Stewardship: Reflections and the Road Ahead. Infectious disease clinics of North America, 37(4), xiii-xiv. (Read full publication)

    Letter

    1. Babbel D, Sutton J, Rose R, Yarbrough P, Spivak E (2018). Application of the DRIP Score at a Veterans Affairs Hospital. Antimicrobial agents and chemotherapy, 62(3), e02277-17.
    2. Babbel D, Sutton J, Rose R, Yarbrough P, Spivak E (2018). Application of the DRIP Score at a Veterans Affairs Hospital. Antimicrobial agents and chemotherapy, 62(3), (Read full publication)
    3. Tritle BJ, Timbrook TT, Fisher MA, Spivak E (2020). Penicillin as a Potential Agent for Dual β-Lactam Therapy for Enterococcal Endocarditis. Clinical infectious diseases, 70(6), 1263-1264.
    4. Tritle BJ, Timbrook TT, Fisher MA, Spivak E (2020). Penicillin as a Potential Agent for Dual ß-Lactam Therapy for Enterococcal Endocarditis. Clinical infectious diseases, 70(6), 1263-1264. (Read full publication)
    5. Spivak ES, Cosgrove SE, Srinivasan (2017). Reply to Schouten et al. Clinical infectious diseases, 64(9), 1296. (Read full publication)
    6. Fabre V, Spivak ES, Keller S (2020). Viewing the Community-acquired Pneumonia Guidelines Through an Antibiotic Stewardship Lens. American journal of respiratory and critical care medicine, 201(6), 745-746.
    7. Fabre V, Spivak ES, Keller S (2020). Viewing the Community-acquired Pneumonia Guidelines through an Antibiotic Stewardship Lens. American journal of respiratory and critical care medicine, 201(6), 745-746. (Read full publication)
    8. Advani SD, Schwartz IS, Spivak ES, Sutton J (2020). Re: 'Antibiotic Treatment for 6 Days Versus 12 Days in Patients With Severe Cellulitis' by Cranendonk Et Al. Clinical microbiology and infection, 26(5), 654-655.
    9. Advani SD, Schwartz IS, Spivak ES, Sutton J (2020). Re: 'Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis' by Cranendonk et al. Clinical microbiology and infection, 26(5), 654-655. (Read full publication)

  • News & Podcasts

    News

    Podcasts